Cabaletta Bio Inc (CABA)
4.26
+0.27
(+6.77%)
USD |
NASDAQ |
Sep 27, 16:00
4.26
0.00 (0.00%)
After-Hours: 20:00
Cabaletta Bio SG&A Expense (Annual): 19.24M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 19.24M |
December 31, 2022 | 14.84M |
December 31, 2021 | 13.82M |
Date | Value |
---|---|
December 31, 2020 | 12.46M |
December 31, 2019 | 7.012M |
December 31, 2018 | 1.726M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
7.012M
Minimum
2019
19.24M
Maximum
2023
13.47M
Average
13.82M
Median
2021
SG&A Expense (Annual) Benchmarks
NovaBay Pharmaceuticals Inc | 12.83M |
Palatin Technologies Inc | 15.29M |
iBio Inc | 11.67M |
Theriva Biologics Inc | 7.12M |
Oragenics Inc | 5.452M |